Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2022 September;66(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2022 September;66(3):229-33

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW  PET/CT IMAGING IN AUTOIMMUNE DISORDERS 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2022 September;66(3):229-33

DOI: 10.23736/S1824-4785.22.03456-2

Copyright © 2022 EDIZIONI MINERVA MEDICA

lingua: Inglese

The role of [18F]FDG PET/CT in paraneoplastic autoimmune disorders: an umbrella review

Barbara MUOIO 1, 2, Domenico ALBANO 3, Francesco DONDI 3, Francesco BERTAGNA 3, Salvatore ANNUNZIATA 4, Francesco FIZ 5, Arnoldo PICCARDO 5, Ramin SADEGHI 6, Giorgio TREGLIA 7, 8, 9

1 Department of Oncology, Geneva University Hospitals, Geneva, Switzerland; 2 Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; 3 Department of Nuclear Medicine, Spedali Civili di Brescia, University of Brescia, Brescia, Italy; 4 Unit of Nuclear Medicine, Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, TracerGLab, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy; 5 Department of Nuclear Medicine, E.O. Ospedali Galliera, Genoa, Italy; 6 Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; 7 Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; 8 Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; 9 Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland



Paraneoplastic autoimmune disorders (PAD) are a group of autoimmune diseases associated with neoplasms. Several evidence-based articles (systematic reviews and meta-analyses) have reported data about the role of positron emission tomography (PET) and related hybrid modalities (e.g., PET/CT) using 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) in patients with PAD. We performed an umbrella review of published systematic reviews and meta-analyses in this setting to provide an evidence-based summary and suggestions for further studies. Several databases were searched to find systematic reviews and meta-analysis on [18F]FDG PET/CT in PAD. Evidence-based data support the use of [18F]FDG PET/CT in patients with suspected PAD for investigating an underlying malignancy even if it is still unclear whether [18F]FDG PET/CT should be performed after negative/inconclusive conventional imaging or as part of the initial workup of PAD.


KEY WORDS: Positron-emission tomography; Nuclear medicine; Multimodal imaging; Autoimmune diseases

inizio pagina